Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Journal: International journal of oncology
Published: February 12, 2023
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Journal: ESMO open
Published: October 08, 2021
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
Journal: Current therapeutic research, clinical and experimental
Published: April 15, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Journal: Clinical lung cancer
Published: April 02, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: February 15, 2021
Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors.
Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors.
Journal: In vivo (Athens, Greece)
Published: November 06, 2020
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Journal: Cancer discovery
Published: November 03, 2020
Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Journal: Anticancer research
Published: October 30, 2020
Antibiotics and Immunotherapy: Too Much of Anything is Bad!
Journal: European urology
Published: July 21, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 09, 2020
Intervention strategies for microbial therapeutics in cancer immunotherapy.
Journal: Immuno-oncology technology
Published: May 20, 2020
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 16, 2020
Last Updated: 09/26/2026